Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of MB66 Vaginal Film for HIV and HSV Prevention
NCT02579083Phase 1Completed
- Sponsor
- KBio
- Start
- Jan 2016
- Primary completion
- Jul 2018
- Modality
- Transdermal Patches, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of MB66 in human immunodeficiency virus infection (HIV) and herpes simplex virus infection (3 arms), sponsored by KBio. Primary endpoint: Incidence of Grade 2 or higher Adverse Events deemed related to study product at Day 10. Started Jan 2016; status: completed.
02
Drugs
MB66
03
Conditions
human immunodeficiency virus infection (HIV)herpes simplex virus infection
Beyond the preview
Go deeper on NCT02579083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579083.